Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 15/20 | 0.54 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473000 | 0.87 | SCD (0.49) | SCDSCD5KDM4EALDH1A1HPGD | |
| SCHEMBL473052 | 0.86 | SCD (0.73) | SCDSCD5 | |
| SCHEMBL4543845 | 0.85 | SCD (0.74) | SCDSCD5 | |
| SCHEMBL27765269 | 0.83 | SCD (0.51) | SCDSCD5MAPT | |
| SCHEMBL473061 | 0.82 | SCD (0.45) | SCDSCD5MAPT | |
| SCHEMBL473059 | 0.82 | SCD (0.73) | SCDSCD5KDM4EALDH1A1HPGD | |
| SCHEMBL3102945 | 0.79 | SCD (0.54) | SCDSCD5KDM4EALDH1A1HPGD | |
| SCHEMBL3020613 | 0.78 | SCD (0.62) | SCDSCD5 | |
| SCHEMBL473021 | 0.76 | SCD (0.46) | SCDSCD5 | |
| SCHEMBL4542008 | 0.75 | SCD (0.54) | SCDSCD5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099793-B1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC (CA) | 2012-02-01 | — | — | EP | disclosed |
| US-8063224-B2 | [5-(5-{4-[2-(Trifluoromethyl)phenoxy]piperidin-1-yl}-1,3,4-thiadiazol-2-yl)-2H-tetrazol-2-yl]acetic acid; metabolic disorders,antidiabetic, hypoglycemic agent; obesity, insulin resistance, liver steatosis, atherosclerosis, neurological disease, dyslipidemia, hyperlipidemia, low HDL, and high LDL | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |